The Transmission of Malaria and How It Spreads

Malaria spreads almost exclusively through the bite of infected female Anopheles mosquitoes, which inject microscopic parasites called Plasmodium into your skin while feeding on your blood. The process is not a simple handoff: the parasite undergoes a complex, multi-stage journey inside both the mosquito and the human host, and a surprising number of biological, environmental, and genetic factors determine whether any single bite actually leads to disease or further transmission.

What Happens During a Bite

When an infected Anopheles mosquito lands on you, it does not immediately find a blood vessel. It probes the skin, inserting its mouthparts into the outer tissue layers while searching for a source of blood. During this probing, the mosquito deposits Plasmodium sporozoites, the infectious stage of the parasite, into the skin outside blood vessels. The sporozoites are motile: they glide through the tissue, actively seeking out and penetrating blood vessels in the dermis or deeper layers beneath the skin.¹ Once a sporozoite enters the bloodstream, it travels to the liver to begin the next phase of its life cycle.

Not all the deposited sporozoites make it to the liver. Research in mouse models found that roughly half of the parasites injected during a bite remain in the skin. About a tenth of those develop locally in the epidermis, dermis, and even inside hair follicles, where they can survive for weeks. This skin-stage development can produce merozoites, the form that infects red blood cells, though this pathway frequently fails to complete.² The main route of infection still runs through the liver, but the fact that parasites linger and develop in the skin adds a wrinkle to how the immune system first encounters the invader.

From the Liver to the Blood and Back to the Mosquito

Sporozoites that reach the liver invade liver cells and multiply silently over roughly a week. You feel nothing during this stage. Eventually, the liver cells burst, releasing thousands of merozoites into the bloodstream. These merozoites invade red blood cells, consume hemoglobin, multiply further, and then rupture the red cells in synchronized waves. That cyclical destruction is what produces the classic symptoms of malaria: fever, chills, and sweating recurring every two or three days depending on the species.

Transmission back to a mosquito depends on a specialized form of the parasite called the gametocyte. A small fraction of blood-stage parasites differentiate into male and female gametocytes, which circulate in the bloodstream without causing symptoms. When a mosquito takes a blood meal from someone carrying gametocytes, those cells enter the mosquito’s midgut and mature into gametes, which fuse and eventually produce new sporozoites that migrate to the mosquito’s salivary glands, completing the cycle.³ Without gametocytes in the blood, a person might be sick with malaria but unable to pass it on.

How Mosquitoes Find You, and Why Infection Makes It Worse

Anopheles mosquitoes track you down using a layered set of cues. Carbon dioxide from your breath draws them toward your general vicinity, but CO₂ alone is not enough. Field experiments showed that no mosquitoes were caught near a CO₂ source unless body heat was also present, and heat proved more important than humidity or visual cues for the final landing decision.⁴ Dark-colored objects also attract investigation by eye, though they are less decisive than heat or CO₂ for triggering an actual bite.

Here is where things get unsettling: the malaria parasite appears to manipulate this system to its advantage. In mouse studies, infected animals became more attractive to mosquitoes during the window when they carried high levels of transmissible gametocytes, after acute symptoms had subsided. The infected mice emitted higher overall levels of volatile chemicals from their skin.⁵ The same pattern holds in people. A study of Kenyan children found that those infected with Plasmodium produced greater amounts of specific aldehydes, including heptanal, octanal, and nonanal, that mosquito antennae can detect. Adding heptanal alone to the odor of a parasite-free person made it more attractive to mosquitoes in lab tests.⁶ In effect, the parasite may be tuning the host’s body odor to draw in more mosquitoes at exactly the right moment for onward transmission.

Asymptomatic Carriers and the Silent Reservoir

A major obstacle to eliminating malaria is that many infected people feel perfectly fine. In areas where malaria is common, repeated exposure builds partial immunity that keeps parasite levels low enough to avoid symptoms while still allowing gametocytes to circulate. A study in a high-transmission area of Ghana found that even among schoolchildren with parasite densities too low for a standard microscope to detect, about a fifth of those carrying gametocytes were still infectious to Anopheles mosquitoes in laboratory feeding experiments.⁷ A smaller study in an Indian city identified asymptomatic carriers primarily among migrant populations, who may sustain low-level transmission in areas that would otherwise see very little malaria.⁸

Standard rapid tests and microscopy miss many of these low-density infections. Molecular tools like PCR and LAMP assays can detect parasites at far lower concentrations, and are increasingly seen as necessary for elimination programs that need to find every carrier, not just the obviously sick ones.⁹ One assay tested against both P. falciparum and P. vivax detected parasites at concentrations as low as 0.1 to 2 parasites per microliter of blood, well below the threshold of a trained microscopist.¹⁰

The Relapse Problem With Plasmodium vivax

Not all malaria species behave the same way after reaching the liver. Plasmodium vivax, the most geographically widespread species, has a trick that P. falciparum lacks. Some of its sporozoites do not immediately begin multiplying. Instead, they go dormant inside liver cells as so-called hypnozoites, where they can sit silently for weeks, months, or even years before reactivating and causing a new round of blood-stage infection.¹¹ This means a person can clear all parasites from their blood, feel completely recovered, and then relapse without being bitten again.

The timing and frequency of relapses vary by strain and geography. Some tropical strains relapse within weeks, while strains from temperate regions can remain dormant for many months, likely an adaptation that allows the parasite to wait out seasons when mosquitoes are absent.¹² Killing hypnozoites requires a specific class of drug, primaquine or tafenoquine, which most standard antimalarials cannot do. This makes P. vivax disproportionately difficult to eliminate: even after you clear every active case, the dormant liver reservoir keeps seeding new infections.

Non-Mosquito Routes of Transmission

Although mosquito bites account for the vast majority of malaria cases, there are other ways the parasite can spread. Transfusion-transmitted malaria occurs when blood from an infected donor reaches a recipient, because Plasmodium parasites live inside red blood cells and can survive in stored blood products.¹³ A review of non-imported malaria cases in Spain, a non-endemic country, documented cases linked to blood transfusion, organ transplantation, congenital transmission from mother to newborn, needlestick exposures in healthcare settings, and shared needles among intravenous drug users.¹⁴ These routes are uncommon compared with mosquito transmission but are worth understanding, especially for blood banks and transplant programs in countries that receive travelers from endemic regions.

When Monkey Malaria Jumps to Humans

Plasmodium knowlesi is a species that naturally infects macaque monkeys in Southeast Asia. Over the past two decades it has been recognized as a significant cause of human malaria in parts of Malaysia, Borneo, and surrounding areas. Mathematical modeling of its transmission dynamics found that human infections are overwhelmingly driven by spillover from the large reservoir of infected macaques rather than by sustained human-to-human-via-mosquito chains. In the model, macaques infected more than six times as many mosquitoes as humans did, and only one extreme parameter combination out of over a thousand tested produced a scenario where human-to-human transmission alone could sustain itself.¹⁵ This means P. knowlesi is primarily a zoonotic threat, and controlling it requires thinking about the monkey-mosquito cycle, not just the human one.

Climate, Land Use, and Where Transmission Thrives

Temperature is one of the strongest environmental drivers of malaria transmission. Warmer conditions speed up mosquito reproduction, increase biting frequency, and shorten the time the parasite needs to develop inside the mosquito. A multi-country study across Sub-Saharan Africa found that each one-degree Celsius rise in temperature was associated with roughly a 1.8-fold increase in malaria risk among children under five, though the relationship was not linear: at very high temperatures, risk actually declined.¹⁶ Daily temperature swings matter too, not just averages. Lab and field data showed that fluctuations around cooler mean temperatures actually speed up parasite development compared with a constant temperature at the same average, while fluctuations around already-hot means can slow things down. At the geographic fringes of malaria range, this means transmission could extend to slightly cooler zones than models based on constant temperatures would predict.¹⁷

Deforestation reshapes transmission in complex ways that depend on the local mosquito species. In areas of Sub-Saharan Africa dominated by Anopheles gambiae and Anopheles funestus, deforestation was linked to roughly a quarter to a third increase in childhood malaria, likely because forest clearing creates sun-warmed puddles and open habitats these species favor.¹⁸ In the Amazon, the pattern is more nuanced. The primary vector there, Anopheles darlingi, clusters its larvae at the edges where forest meets cleared land. Settlers living within 400 meters of these forest fringes had 2.6 times the malaria risk, and as deforestation advanced further and the forest edge retreated, transmission actually decreased in previously cleared areas.¹⁹

Insecticide Resistance Is Undermining Bed Nets

Insecticide-treated bed nets have been one of the most effective tools against malaria over the past two decades, but the insecticides they rely on, primarily pyrethroids, are losing their punch. Across West Africa, pyrethroid resistance in Anopheles gambiae populations is widespread and driven by multiple mechanisms at once, including genetic mutations in the insecticide’s target and overproduction of detoxification enzymes.²⁰ In southern Africa, a single genetic variant in Anopheles funestus was shown to directly reduce the effectiveness of insecticide-treated bed nets at preventing malaria transmission, with evidence that the variant had been selected for partly by the scale-up of bed net use itself.²¹

Newer bed nets combine a pyrethroid with piperonyl butoxide, a chemical that blocks the mosquito’s detox enzymes, partially restoring effectiveness against resistant populations. But the underlying arms race between insecticides and mosquito evolution is ongoing, and sustaining bed net effectiveness will require rotating insecticides and developing entirely new classes of chemicals.

Drug Resistance in the Parasite

The parasite has its own resistance problems. Artemisinin-based combination therapies are the frontline treatment for P. falciparum malaria worldwide, but mutations in a gene called kelch13 cause the parasite to clear more slowly from the blood after treatment. This partial artemisinin resistance was first detected across mainland Southeast Asia, from southern Vietnam to central Myanmar.²² The concern now is that the same mutations, or functionally equivalent ones, are appearing independently in Africa. Surveys in western Kenya identified four validated kelch13 resistance mutations circulating among schoolchildren.²³ If partner drugs also fail, full treatment failure becomes possible, as already happened in parts of the Mekong region.²⁴

An Urban Mosquito Invading Africa

Most African malaria mosquitoes breed in rural puddles, ditches, and farmland. That is one reason Africa’s rapidly growing cities have historically been somewhat buffered from malaria. But Anopheles stephensi, a species native to South Asia that thrives in urban water containers, cisterns, and construction sites, has now established itself in the Horn of Africa. It was first linked to unusual urban malaria outbreaks in Djibouti City starting in 2012, with increasingly severe outbreaks reported each year afterward. The species has since been confirmed in Ethiopia and Sudan, prompting a WHO vector alert.²⁵ Modeling suggests that if An. stephensi spreads further across the continent, hundreds of millions of urban residents who previously faced minimal malaria exposure could be at risk.²⁶ Its rapid spread is considered one of the most serious emerging threats to malaria control in Africa today.²⁷

Why Some People Are Naturally More Resistant

The long evolutionary history between humans and Plasmodium has left genetic marks on human populations in malaria-endemic regions. The best-known example is sickle cell trait, where carrying one copy of the sickle hemoglobin gene (HbAS) provides substantial protection against severe falciparum malaria. The exact mechanisms are still debated, but the protective effect has been confirmed across many studies and is strong enough to have maintained the sickle cell gene at high frequencies in African populations despite its harmful effects when two copies are inherited.²⁸

Sickle cell is far from the only protective variant. Alpha thalassemia, certain blood group polymorphisms, and variations in red blood cell surface proteins all influence susceptibility. Interestingly, having both sickle cell trait and alpha thalassemia at the same time can cancel out the malaria protection that sickle cell trait would otherwise provide, which may explain why sickle cell trait is less common in Mediterranean populations where alpha thalassemia is widespread.²⁹ On the flip side, the Duffy blood group antigen serves as a necessary docking point for P. vivax to enter red blood cells. Most people of West African descent lack the Duffy antigen entirely, which historically made them essentially resistant to vivax malaria, though rare exceptions have been documented.

The Mosquito’s Own Immune System

Transmission is not a frictionless highway for the parasite inside the mosquito, either. Anopheles mosquitoes have their own innate immune system, and it mounts responses at multiple stages of Plasmodium development. When the parasite penetrates the mosquito’s midgut wall as an ookinete, the mosquito’s immune cells and signaling pathways actively attack it.³⁰ Immune signaling triggered in the midgut can spread systemically, activating defenses elsewhere in the mosquito’s body as well.³¹ In many natural infections, these defenses kill the vast majority of parasites before they can reach the salivary glands. This bottleneck inside the mosquito is one reason researchers are interested in amplifying it as a control strategy.

Vaccines That Target the Transmission Cycle

The R21/Matrix-M vaccine, developed at the University of Oxford and now recommended by WHO for children in endemic areas, targets the circumsporozoite protein on the surface of sporozoites, the stage injected by the mosquito. In a phase 3 trial across four African countries, vaccine efficacy against clinical malaria over 12 months was about 75% at seasonal transmission sites and 68% at sites with year-round transmission. Younger children (aged 5 to 17 months) showed the highest efficacy, reaching 79% at seasonal sites.³² This is a pre-erythrocytic vaccine, meaning it works by stopping sporozoites before they establish a liver infection, reducing both disease and, indirectly, onward transmission.

Gene Drives and Engineered Mosquitoes

One of the most ambitious approaches to breaking malaria transmission involves rewriting the mosquito’s own DNA. Gene drive technology uses CRISPR-based systems to push genetic modifications through wild mosquito populations far faster than normal inheritance would allow. There are two broad strategies: population suppression, which aims to crash mosquito numbers by disrupting fertility or skewing sex ratios, and population modification, which leaves mosquitoes alive but genetically unable to transmit the parasite.³³

A gene drive strain of Anopheles gambiae called AgNosCd-1 was engineered to carry antiparasite molecules. In laboratory cage trials, the drive achieved 98 to 100% inheritance in both sexes and spread to every mosquito in small populations within six to ten generations after a single release of modified males.³⁴ A separate approach engineered Anopheles gambiae to secrete antimicrobial peptides in the midgut, which hampered parasite development and delayed the release of infectious sporozoites. Epidemiological modeling suggested this modification could break the transmission cycle across a range of conditions.³⁵

Gene drives remain in the lab and in carefully contained trials. The ecological and ethical questions around releasing self-propagating genetic modifications into wild ecosystems are significant, and no gene drive mosquito has yet been released in an open field setting. But given the resistance problems facing both insecticides and drugs, the technology represents one of the few genuinely novel tools on the horizon for a disease that still kills hundreds of thousands of people each year.

An Ancient Relationship Still Evolving

The story of malaria transmission is inseparable from the evolutionary history of the parasites themselves. For decades, scientists assumed P. falciparum had co-evolved with humans and our ancestors over millions of years, while P. vivax was thought to have jumped from Asian macaques. Genomic studies of Plasmodium species found in wild chimpanzees and gorillas upended both ideas. P. falciparum and P. vivax both originated from parasites infecting African apes, not from ancient human lineages or Asian primates.³⁶ For P. vivax, genomic analyses suggest a severely bottlenecked lineage emerged out of Africa from an ancestral stock that infected both humans and apes, then underwent rapid population growth as it spread across the globe.³⁷ Understanding these origins matters because the ape parasites still circulating in African forests represent a potential source of new cross-species jumps, much as P. knowlesi crossed from macaques to humans in Southeast Asia. Malaria is not just one old disease with a fixed playbook. It is a family of parasites that have crossed species boundaries before and could do so again.